Key Points
-
The Erbb family consists of four closely related type 1 transmembrane tyrosine kinase receptors: the epidermal growth factor receptor (EGFR; also known as ERBB1), ERBB2, ERBB3 and ERBB4. Signalling through the Erbb family underpins many of the cellular activities on which cell survival and function depend.
-
EGFR, ERBB2 and ERBB3 are all implicated in the development and progression of cancer, and heterodimerization of the receptors plays a crucial part in their function. The role of ERBB4 in oncogenesis is less clear and this receptor might be involved in inhibition of cell growth rather than proliferation.
-
Aberrant ERBB2 expression or function has been implicated in the evolution of both breast and gastric cancers and is evident in other cancer types, including ovarian and salivary gland tumours. This receptor has proved to be a potent target for anticancer therapies, including antibody-based therapies to prevent ligand binding, dimer formation or antibody-dependent cell-mediated cytotoxicity, and direct kinase inhibition to prevent molecular activation and recruitment of downstream signalling partners.
-
New strategies against ERBB2 include Erbb tyrosine kinase inhibitors, heat shock protein 90 inhibitors, Erbb dimerization inhibitors and antibody–chemotherapy conjugates. All of these approaches have shown substantial clinical activity in patients who have progressed on trastuzumab, an anti-ERBB2 monoclonal antibody.
-
The extent of the role of ERBB3 is now emerging and considerable research efforts are focused on developing new therapies that target ERBB3.
-
ERBB3-specific monoclonal antibodies are now under evaluation, and data suggest that individual tyrosine kinase inhibitors might inhibit ERBB3 activation or its interaction with downstream signalling components.
-
Preventing the dimerization of ERBB3 with its signalling partners, in particular ERBB2 with which it forms the most potent mitogenic signalling dimer, might offer an effective method of preventing oncogenic signalling across the Erbb network.
Abstract
Aberrant receptor expression or functioning of the epidermal growth factor receptor (Erbb) family plays a crucial part in the development and evolution of cancer. Inhibiting the signalling activity of individual receptors in this family has advanced the treatment of a range of human cancers. In this Review we re-evaluate the role of two important family members, ERBB2 (also known as HER2) and ERBB3 (also known as HER3), and explore the mechanisms of action and preclinical and clinical data for new therapies that target signalling through these pivotal receptors. These new therapies include tyrosine kinase inhibitors, antibody–chemotherapy conjugates, heat-shock protein inhibitors and antibodies that interfere with the formation of ERBB2–ERBB3 dimers.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Hynes, N. E. & Lane, H. A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nature Rev. Cancer 5, 341–354 (2005).
Mendelsohn, J. & Baselga, J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol. 21, 2787–2799 (2003).
Yarden, Y. & Sliwkowski, M. X. Untangling the ErbB signalling network. Nature Rev. Mol. Cell Biol. 2, 127–137 (2001).
Olayioye, M. A., Neve, R. M., Lane, H. A. & Hynes, N. E. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 19, 3159–3167 (2000).
Ferguson, K. M. et al. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol. Cell 11, 507–517 (2003). This paper reported the crystal structure of EGFR in its unbound 'closed' state in which the dimerization arm is hidden in the folded molecule, highlighting the need for a ligand-driven conformational change to allow receptor dimerization.
Cho, H. S. et al. Structure of the extracellular region of HER3 reveals an interdomain tether. Science 297, 1330–1333 (2002).
Burgess, A. W. et al. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol. Cell 12, 541–552 (2003).
Ogiso, H. et al. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 110, 775–787 (2002).
Zhang, X., Gureasko, J., Shen, K., Cole, P. A. & Kuriyan, J. An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125, 1137–1149 (2006).
Jeffrey, P. D. et al. The crystal structure of human cyclin H. Nature 376, 313–320 (1995).
Hubbard, S. R. EGF receptor activation: push comes to shove. Cell 125, 1029–1031 (2006).
Sierke, S. L., Cheng, K., Kim, H. H. & Koland, J. G. Biochemical characterization of the protein tyrosine kinase homology domain of the ErbB3 (HER3) receptor protein. Biochem. J. 322, 757–763 (1997).
Garrett, T. P. et al. The crystal structure of truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol. Cell 11, 495–505 (2003). This paper reported the crystal structure of ERBB2, showing that this receptor exists in an 'open' conformation and is constitutively available for dimerization.
Berger, M. B., Mendrola, J. M. & Lemmon, M. A. ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface. FEBS Lett. 569, 332–336 (2004).
Feng, S. M. et al. The HER4 cytoplasmic domain, but not its C-terminus, inhibits mammary cell proliferation. Mol. Endocrinol. 21, 1861–1876 (2007).
Tzahar, E. et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol. Cell. Biol. 16, 5276–5287 (1996).
Pinkas-Kramarski, R. et al. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J. 15, 2452–2467 (1996). This paper showed the lack of tyrosine kinase activity of the intracellular domain of ERBB3 and the ability of other Erbb members to transphosphorylate this region of the ERBB3 molecule and facilitate ERBB3-mediated signalling.
Hsieh, A. C. & Moasser, M. M. Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br. J. Cancer 97, 453–457 (2007).
Lee-Hoeflich, S. T. et al. A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy. Cancer Res. 68, 5878–5887 (2008).
Slamon, D. J. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177–182 (1987).
Owens, M. A. et al. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin. Breast Cancer 5, 63–69 (2004).
Yaziji, H. et al. HER-2 testing in breast cancer using parallel tissue-based methods. J. Am. Med. Assoc. 291, 1972–1977 (2004).
Vermeij, J. et al. Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers. BMC Cancer 8, 3 (2008).
Jaehne, J. et al. Expression of Her2/neu oncogene product p185 in correlation to clinicopathological and prognostic factors of gastric carcinoma. J. Cancer Res. Clin. Oncol. 118, 474–479 (1992).
Cornolti, G. et al. Amplification and overexpression of HER2/neu gene and HER2/neu protein in salivary duct carcinoma of the parotid gland. Arch. Otolaryngol. Head Neck Surg. 133, 1031–1036 (2007). Refs 19–25 underscore the frequency and prognostic importance of ERBB2 overexpression in a range of human cancers, including breast, ovarian, gastric and salivary duct carcinomas.
Zuo, T. et al. FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell 129, 1275–1286 (2007).
Liu, E. et al. The HER2 (c-erbB-2) oncogene is frequently amplified in in situ carcinomas of the breast. Oncogene 7, 1027–1032 (1992).
Park, K., Han, S., Kim, H. J., Kim, J. & Shin, E. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry. Histopathology 8, 702–707 (2006).
Cappuzzo, F., Bemis, L. & Varella-Garcia, M. HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer. N. Engl. J. Med. 354, 2619–2621 (2006).
Wang, S. E. et al. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 10, 25–38 (2006).
Holbro, T. et al. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc. Natl Acad. Sci. USA 100, 8933–8938 (2003).
Cantley, L. C. The phosphoinositide 3-kinase pathway. Science 296, 1655–1657 (2002).
Prigent, S. A. & Gullick, W. J. Identification of c-erbB-3 binding sites for phosphatidylinositol 3′-kinase and SHC using an EGF receptor/c-erbB-3 chimera. EMBO J. 13, 2831–2841 (1994).
Soltoff, S. P., Carraway, K. L. 3rd, Prigent, S. A., Gullick, W. G. & Cantley, L. C. ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol. Cell. Biol. 14, 3550–3558 (1994).
Hellyer, N. J., Cheng, K. & Koland, J. G. ErbB3 (HER3) interaction with the p85 regulatory subunit of phosphoinositide 3-kinase. Biochem. J. 333, 757–763 (1998).
Sergina, N. V. et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445, 437–441 (2007). This paper reported the capacity for ERBB3 signalling to be upregulated to compensate for inhibition of other Erbb family members.
Engelman, J. A. et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316, 1039–1043 (2007).
Wheeler, D. L. et al. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 27, 3944–3956 (2008).
Bobrow, L. G., Millis, R. R., Happerfield, L. C. & Gullick, W. J. c-erbB-3 protein expression in ductal carcinoma in situ of the breast. Eur. J. Cancer 33, 1846–1850 (1997).
Quinn, C. M. et al. C-erbB-3 protein expression in human breast cancer: comparison with other tumor variables and survival. Histopathology 25, 247–252 (1994).
Travis, A. et al. C-erbB-3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators. Br. J. Cancer 74, 229–233 (1996).
Siegel, P. M., Ryan, E. D., Cardiff, R. D. & Muller, W. J. Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer. EMBO J. 18, 2149–2164 (1999).
Atlas, E. et al. Heregulin is sufficient for the promotion of tumorigenicity and metastasis of breast cancer cells in vivo. Mol. Cancer Res. 1, 165–175 (2003).
Krane, I. M. & Leder, P. NDF/heregulin induces persistence of terminal end buds and adenocarcinomas in the mammary glands of transgenic mice. Oncogene 12, 1781–1788 (1996).
Tsai, M. S., Shamon-Taylor, L. A., Mehmi, I., Tang, C. K. & Lupu, R. Blockage of heregulin expression inhibits tumorigenicity and metastasis of breast cancer. Oncogene 22, 761–768 (2003).
Rajkumar, T., Stamp, G. W., Hughes, C. M. & Gullick, W. J. C-erbB3 protein expression in ovarian cancer. Clin. Mol. Pathol. 49, M199–M202 (1996).
Tanner, B. et al. ErbB-3 predicts survival in ovarian cancer. J. Clin. Oncol. 24, 4317–4323 (2006). This paper highlights the prognostic importance of ERBB3: high levels of ERBB3 expression are associated with a significantly shorter survival time compared with patients with tumours that overexpress ERBB2.
Campiglio, M., Ali, S., Knyazev, P. G. & Ullrich, A. Characteristics of EGFR family-mediated HRG signals in human ovarian cancer. J. Cell. Biochem. 73, 522–532 (1999).
Engelman, J. A. et al. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancers cell lines. Proc. Natl Acad. Sci. USA 102, 3788–3793 (2005).
Gregory, C. W. et al. Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth. Clin. Cancer Res. 11, 1704–1712 (2005).
Mellinghoff, I. K. et al. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 6, 517–527 (2004).
Hudziak, R. M. et al. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol. Cell. Biol. 9, 1165–1173 (1989).
Baselga, J. et al. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 58, 2825–2831 (1998).
Moody, S. E. et al. Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell 2, 451–461 (2002).
Ursini-Siegel, J. et al. Insights from transgenic mouse models of ERBB2-induced breast cancer. Nature Rev. Cancer 7, 389–397 (2007).
Hirata, A. et al. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells. Cancer Res. 65, 4253–4260 (2005).
Ritter, C. A. et al. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin. Cancer Res. 13, 4909–4919 (2007).
Gril, B. et al. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J. Natl. Cancer Inst. 100, 1092–1103 (2008).
Drebin, J. A. et al. Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecular exert synergistic anti-tumor effects in vivo. Oncogene 2, 273–277 (1988).
Carter, P. et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl Acad. Sci. USA 89, 4285–4289 (1992).
Cho, H. S. et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421, 756–760 (2003).
Izumi, Y., Xu, L., di Tomaso, E., Fukumura, D. & Jain, R. K. Tumor biology: Herceptin acts as an anti-angiogenic cocktail. Nature 416, 279–280 (2002).
Lane, H. A. et al. ErbB2 potentiates breast tumor proliferation through modulation of p27Kip1–Cdk2 complex formation: receptor overexpression does not determine growth dependency. Mol. Cell. Biol. 20, 3210–3223 (2000).
Le, X. F. et al. The role of cyclin-dependent kinase inhibitor p27Kip1 in anti-HER2 antibody-induced G1 cell cycle arrest and tumor growth inhibition. J. Biol. Chem. 278, 23441–23450 (2003).
Longva, K. E., Pedersen, N. M., Haslekås, C., Stang, E. & Madshus, I. H. Herceptin-induced inhibition of ErbB2 signaling involves reduced phosphorylation of Akt but not endocytic down-regulation of ErbB2. Int. J. Cancer 116, 359–367 (2005).
Nagata, Y. et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6, 117–127 (2004).
Cuello. M. et al. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res. 61, 4892–4900 (2001).
Le, X. et al. Anti-HER2 antibody trastuzumab inhibits CDK2-mediated nPAt and histone H4 expression via the PI3K pathway. Cell Cycle 5, 1654–1661 (2006).
Berns, K. et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12, 395–402 (2007).
Eichhorn, P. J. et al. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res. 68, 9221–9230 (2008).
Wehrman, T. S. et al. A system for quantifying dynamic protein interactions defines a role for Herceptin in modulating ErbB2 interactions. Proc. Natl Acad. Sci. USA 103, 19063–19068 (2006).
Clynes, R. A., Towers, T. L., Presta, L. G. & Ravetch, J. V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nature Med. 6, 443–446 (2000).
Musolino, A. et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J. Clin. Oncol. 26, 1789–1796 (2008).
Molina, M. A. et al. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res. 61, 4744–4749 (2001).
Baselga, J. et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol. 14, 737–744 (1996).
Cobleigh, M. A. et al. Multinational study of the efficacy and safety of humanized anti-HER2 antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic breast disease. J. Clin. Oncol. 17, 2639–2648 (1999).
Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783–792 (2001).
Marty, M. et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J. Clin. Oncol. 23, 4265–4274 (2005).
Romond, E. H. et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353, 1673–1684 (2005).
Piccart-Gebhart, M. J. et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353, 1659–1672 (2005).
Joensuu, H. et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N. Engl. J. Med. 354, 809–820 (2006).
Smith, I. et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369, 29–36 (2007).
Mohsin, S. K. et al. Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J. Clin. Oncol. 23, 2460–2468 (2005).
Lazaridis, G., Pentheroudakis G. & Pavlidis N. Integrating trastuzumab in the neoadjuvant treatment of primary breast cancer: Accumulating evidence of efficacy, synergy and safety. Crit. Rev. Oncol. Hematol. 66, 31–41 (2008).
Franklin, M. C. et al. Insights into ErbB signaling from the structure of the ErbB2–pertuzumab complex. Cancer Cell 5, 317–328 (2004).
Hubbard, S. R. EGF receptor inhibition: attacks on multiple fronts. Cancer Cell 7, 287–288 (2005).
Fendly, B. M. et al. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res. 50, 1550–1558 (1990).
Sliwkowski, M. X. et al. Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin. J. Biol. Chem. 269, 14661–14665 (1994).
Lewis, G. D. et al. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol. Immunother. 37, 255–263 (1993).
Schaefer, G., Fitzpatrick, V. D. & Sliwkowski, M. X. γ-Heregulin: a novel heregulin isoform that is an autocrine growth factor for the human breast tumor cell line, MDA-MB-175. Oncogene 15, 1385–1394 (1997).
Fitzpatrick, V. D., Pisacane, P. I., Vandlen, R. L. & Sliwkowski, M. X. Formation of a high affinity heregulin binding site using the soluble extracellular domains of ErbB2 with ErbB3 or ErbB4. FEBS Lett. 431, 102–106 (1998).
Mendoza, N., Philips, G. L., Silva, J., Schwall, R. & Wickramasinghe, D. Inhibition of ligand-mediated HER2 activation in androgen-independent prostate cancer. Cancer Res. 62, 5485–5488 (2002).
Agus, D. B. et al. Targeting ligand activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2, 127–137 (2002). This paper shows that pertuzumab is a humanized monoclonal antibody that inhibits ERBB2 dimerization.
Baselga, J. A new anti-ErbB2 strategy in the treatment of cancer: prevention of ligand-dependent ErbB2 receptor heterodimerization. Cancer Cell 2, 93–95 (2002).
Arteaga, C. L. et al. A phase I–II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer. Clin. Cancer Res. 14, 6277–6283 (2008).
Mullen, P., Cameron, D. A., Hasmann, M., Smyth, J. F. & Langdon, S. P. Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling. Mol. Cancer Ther. 6, 93–100 (2007).
Sakai, K. et al. Pertuzumab, a novel dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway. Cancer Sci. 98, 1498–1503 (2007).
Mann, M. et al. Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterology 120, 1713–1719 (2001).
Cortes, J. et al. Open label, randomized, phase II study of pertuzumab (P) in patients (pts) with metastatic breast cancer (MBC) with low expression of HER2. J. Clin. Oncol. 23 (Suppl.), 3068 (2005).
Nahta, R., Hung, M. C. & Esteva, F. J. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res. 64, 2343–2346 (2004).
Spiridon, C. I. et al. Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo. Clin. Cancer Res. 8, 1720–1730 (2002).
Spiridon, C. I., Guinn, S. & Vitetta, E. S. A comparison of the in vitro and in vivo activities of IgG and F(ab′)2 fragments of a mixture of three monoclonal anti-Her-2 antibodies. Clin. Cancer Res. 10, 3542–3551 (2004).
Portera, C. C. et al. Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. Clin. Cancer Res. 14, 2710–2716 (2008). This paper provides evidence for activity of pertuzumab in combination with trastuzumab in Phase II studies in patients with ERBB2-positive MBC.
Baselga, J. et al. Objective response rate in a phase II multicenter trial of pertuzumab, a HER2 dimerization inhibiting monoclonal antibody in combination with trastuzumab in patients with HER2-positive metastatic breast cancer which has progressed during treatment with trastuzumab. J. Clin. Oncol. 25 (Suppl.), 1004 (2007).
Gelmon, K. A. et al. Results of a Phase II trial of trastuzumab (H) and pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) who had progressed during trastuzumab therapy. J. Clin. Oncol. 26 (Suppl.), 1026 (2008).
Burris, H. A. et al. A phase II study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (MBC). The American Society for Clinical Oncology. [online] (2008).
O'Shaughnessy, J. et al. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. J. Clin. Oncol. 26 (Suppl.), 1015 (2008).
Makhija, S. et al. Results from a Phase II randomized, placebo-controlled, double-blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. J. Clin. Oncol. 25 (Suppl.), 5507 (2007).
Makhija, S. et al. HER3 pathway gene expression analysis in a Phase II study of pertuzumab + gemcitabine vs. gemcitabine + placebo in patients with platinum-resistant epithelial ovarian cancer. J. Clin. Oncol. 26 (Suppl.), 4483 (2008).
Amler, L. et al. in Proceedings of the 99th Annual Meeting of the American Association for Cancer Research, Abstract Number 4483 (San Diego, California, 2008).
Negro, A. et al. erbB2 is required for G protein-coupled receptor signaling in the heart. Proc. Natl Acad. Sci. USA 103, 15889–15893 (2006).
Kiewe, P. et al. Phase I trial of the trifunctional anti-HER2 × anti-CD3 antibody ertumaxomab in metastatic breast cancer. Clin. Cancer Res. 12, 3085–3091 (2006).
Lewis Phillips, G. D. et al. Targeting HER2-positive breast cancer with trastuzumab–DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 68, 9280–9290 (2008).
Austin, C. D. et al. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol. Biol. Cell 15, 5268–5282 (2004).
Spector, N. L. et al. A study of the biological effects of lapatinib (GW572016), a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J. Clin. Oncol. 23, 2502–2512 (2005).
Geyer, C. E. et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 355, 2733–2743 (2006).
Lin, N. U. et al. EGF 105084, a phase II study of lapatinib for brain metastases in patients (pts) with Her2+ breast cancer following trastuzumab (H) based systemic therapy and cranial radiotherapy. J. Clin. Oncol. 25 (Suppl.), 1112 (2007).
Pedersen, K. et al. A naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis. Mol. Cell. Biol. 13 Apr 2009 (doi: 10.1128/MCB.01803-08).
Scaltriti, M. et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J. Natl Cancer Inst. 99, 628–638 (2007).
Konecny, G. E. et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 66, 1630–1639 (2006).
Scaltriti, M. et al. Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene 28, 803−814 (2009).
Burstein, H. J. et al. in 31st San Antonio Breast Cancer Symposium, Abstract Number 37 (San Antonio, Texas, 2008).
Li, D. et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27, 4702–4711 (2008).
Eskens, F. A. et al. A Phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumors. Br. J. Cancer 98, 80–85 (2008).
Freeman, D., Ogbagabriel, S., Rothe, M., Radinsky, R. & Treder, M. in Proceedings of the 99th Annual Meeting of the American Association for Cancer Research, Abstract Number LB-21(San Diego, California, 2008).
Citri, A., Kochupurakkal, B. S. & Yarden, Y. The achilles heel of ErbB-2/HER2: regulation of the Hsp90 chaperone machine and potential for pharmacological intervention. Cell Cycle 3, 51–60 (2004).
Citri, A. et al. Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy. EMBO J. 21, 2407–2417 (2002).
Mimnaugh, E. G., Chavany, C. & Neckers, L. Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. J. Biol. Chem. 271, 22796–22801 (1996).
Münster, P. N., Marchion, D. C., Basso, A. D. & Rosen, N. Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3′-kinase–AKT-dependent pathway. Cancer Res. 62, 3132–3137 (2002).
Modi, S. et al. Phase II trial of the Hsp90 inhibitor tanespimycin (Tan) + trastuzumab (T) in patients (pts) with HER2 positive metastatic breast cancer (MBC). J. Clin. Oncol. 26 (Suppl.), 1027 (2008).
Weinstein, I., B. & Joe, A. Oncogene addiction. Cancer Res. 68, 3077–3078 (2008).
Majumder, P. K. et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nature Med. 10, 594–601 (2004).
Neshat, M. S. et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl Acad. Sci. USA. 98, 10314–10319 (2001).
Steelman, L. S. et al. Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors. Oncogene 27, 4086–4095 (2008).
Engelman, J. A., Luo, J. & Cantley, L. C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nature Rev. Genetics 7, 606–619 (2006).
Vivanco, I. & Sawyers, C. L. The phosphatidylinositol 3-kinase–AKT pathway in human cancer. Nature Rev. Cancer 2, 489–501 (2002).
Yuan, T. L. & Cantley, L. C. PI3K pathway alterations in cancer: variations on a theme. Oncogene 27, 5497–5510 (2008).
Fruman, D. A., Meyers, R. E. & Cantley, L. C. Phosphoinositide kinases. Annu. Rev. Biochem. 67, 481–507 (1998).
Gordon, M. S. et al. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J. Clin. Oncol. 4, 4324–4332 (2006).
Herbst, R. S. et al. Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer. Clin. Cancer Res. 13, 6175–6181 (2007).
de Bono, J. S. et al. Open-label Phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naïve patients with hormone-refractory prostate cancer. J. Clin. Oncol. 25, 257–262 (2007).
Agus, D. B. et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J. Clin. Oncol. 23, 2534–2543 (2005). This paper shows the activity and tolerability of pertuzumab as a single agent in a Phase I study, and that the pharmacokinetic profile is supportive of dosing every 3 weeks.
Modi, S. et al. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER2-over expressing breast cancer: a phase I dose-escalation study. J. Clin. Oncol. 25, 5410–5417 (2007).
Miller, K. et al. Phase I trial of alvespimycin (KOS-1022; 17-DMAG) and trastuzumab (T). J. Clin. Oncol. 25 (Suppl.), 1115 (2007).
Acknowledgements
Support for third-party writing assistance for this manuscript was provided by Genentech USA.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
José Baselga has a consultant/advisory role for Roche, Infinity, Novartis and Exelixis. He receives research funding from GlaxoSmithKline.
Sandra M. Swain is an (unpaid) advisor for GNE and Sanofi-Aventis and has travelled for Sanofi-Aventis. She receives research funding from BMS and GNE.
Related links
Related links
DATABASES
National Cancer Institute Drug Dictionary
FURTHER INFORMATION
Glossary
- Overall survival
-
The total length of time from a particular point, such as diagnosis or initiation of treatment, until the patient succumbs to disease.
- Clinical benefit rate
-
A metric that combines the proportion of patients who achieve any response or stable disease.
- Overall response rate
-
Also known as the objective response rate.The proportion of patients who achieve either a complete or partial response to treatment.
- Progression-free survival
-
The total length of time during and after treatment in which the disease does not get worse.
Rights and permissions
About this article
Cite this article
Baselga, J., Swain, S. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 9, 463–475 (2009). https://doi.org/10.1038/nrc2656
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrc2656
This article is cited by
-
Prevalence and clinicopathological associations of HER2 expression in non-small cell lung cancer: a retrospective study in Jordanian patients
Diagnostic Pathology (2023)
-
Anti-cancer effect of afatinib, dual inhibitor of HER2 and EGFR, on novel mutation HER2 E401G in models of patient-derived cancer
BMC Cancer (2023)
-
HER3 functions as an effective therapeutic target in triple negative breast cancer to potentiate the antitumor activity of gefitinib and paclitaxel
Cancer Cell International (2023)
-
LINC02381 suppresses cell proliferation and promotes apoptosis via attenuating IGF1R/PI3K/AKT signaling pathway in breast cancer
Functional & Integrative Genomics (2023)
-
A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation
Cancer Chemotherapy and Pharmacology (2023)